Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    vx21-121-105 | Cystic Fibrosis
Previous Study | Return to List | Next Study

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05422222
Recruitment Status : Recruiting
First Posted : June 16, 2022
Last Update Posted : June 8, 2023
Sponsor:
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: VX-121/TEZ/D-IVA Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 210 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age
Actual Study Start Date : June 21, 2022
Estimated Primary Completion Date : June 2030
Estimated Study Completion Date : June 2030

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Part A: VX-121/TEZ/D-IVA
Participants will receive VX-121/TEZ/D-IVA in the morning.
 Drug: VX-121/TEZ/D-IVA
Fixed-dose combination for oral administration.
Other Names:
  • VX-121/VX-661/VX-561
  • VX-121/VX-661/CTP-656
  • VX-121/tezacaftor/deutivacaftor
Experimental: Part B: VX-121/TEZ/D-IVA
Participants will receive VX-121/TEZ/D-IVA in the morning with the dose(s) to be based on the outcome of Part A.
 Drug: VX-121/TEZ/D-IVA
Fixed-dose combination for oral administration.
Other Names:
  • VX-121/VX-661/VX-561
  • VX-121/VX-661/CTP-656
  • VX-121/tezacaftor/deutivacaftor


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Part A: Observed Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ, D-IVA, and Relevant Metabolites [ Time Frame: From Day 1 up to Day 22 ]
  2. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: From Day 1 up to Day 50 ]
  3. Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: From Day 1 up to Week 28 ]

Secondary Outcome Measures :
  1. Part B: Absolute Change in Sweat Chloride (SwCl) [ Time Frame: From Baseline Through Week 24 ]
  2. Part B: Observed Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ, D-IVA, and Relevant Metabolites [ Time Frame: From Day 1 up to Week 16 ]
  3. Part B: Drug Acceptability Assessment Using Modified Facial Hedonic Scale [ Time Frame: At Day 1 and Week 24 ]
  4. Part B: Absolute Change in Percent Predicted Forced Expiratory Volume (ppFEV1) [ Time Frame: From Baseline Through Week 24 ]
  5. Part B: Number of Pulmonary Exacerbation (PEx) [ Time Frame: From Baseline Through Week 24 ]
  6. Part B: Number of CF-Related Hospitalizations [ Time Frame: From Baseline Through Week 24 ]
  7. Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score [ Time Frame: From Baseline Through Week 24 ]
  8. Part B: Absolute Change in Body Mass Index (BMI) [ Time Frame: From Baseline at Week 24 ]
  9. Part B: Absolute Change in BMI-for-age Z-score [ Time Frame: From Baseline at Week 24 ]
  10. Part B: Absolute Change in Weight [ Time Frame: From Baseline at Week 24 ]
  11. Part B: Absolute Change in Weight-for-age Z-score [ Time Frame: From Baseline at Week 24 ]
  12. Part B: Absolute Change in Weight-for-length [ Time Frame: From Baseline at Week 24 ]
  13. Part B: Absolute Change in Weight-for-length Z-score [ Time Frame: From Baseline at Week 24 ]
  14. Part B: Absolute Change in Height [ Time Frame: From Baseline at Week 24 ]
  15. Part B: Absolute Change in Height-for-age Z-score [ Time Frame: From Baseline at Week 24 ]
  16. Part B: Absolute Change in Length [ Time Frame: From Baseline at Week 24 ]
  17. Part B: Absolute Change in Length-for-age Z-score [ Time Frame: From Baseline at Week 24 ]
  18. Part B: Proportion of Participants With SwCl <60 millimole per liter (mmol/L) [ Time Frame: From Baseline Through Week 24 ]
  19. Part B: Proportion of Participants With SwCl <30 mmol/L [ Time Frame: From Baseline Through Week 24 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Participants with stable CF and at least 1 TCR mutation (including F508del) in the CFTR gene

Key Exclusion Criteria:

  • History of solid organ, hematological transplantation, or cancer
  • Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)
  • Lung infection with organisms associated with a more rapid decline in pulmonary status

Other protocol defined Inclusion/Exclusion criteria may apply.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05422222


Contacts
Layout table for location contacts
Contact: Medical Information 617-341-6777 medicalinfo@vrtx.com

Locations
Show Show 33 study locations
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier: NCT05422222    
Other Study ID Numbers: VX21-121-105
2021-005930-40 ( EudraCT Number )
First Posted: June 16, 2022    Key Record Dates
Last Update Posted: June 8, 2023
Last Verified: June 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
 Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases